News

Fierce Biotech13h

Xoma adds fading Mural Oncology to portfolio of struggling biotechs

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. | ...
Fierce Biotech17h

Celldex ends esophageal program despite hitting primary endpoint in phase 2 trial

Celldex has stopped development of barzolvolimab in eosinophilic esophagitis (EoE) despite meeting its primary endpoint in a ...
Fierce Biotech13h

Rocket launches from FDA hold, but uncertainty about the biotech’s cash runway looms

The FDA has freed Rocket Pharmaceuticals from a clinical hold, giving the gene therapy developer permission to take flight ...
Fierce Biotech12h

FDA draft recommends overall survival data collection for all cancer trials

More than two years after the Food and Drug Administration held a public workshop on measuring overall survival (OS) in ...
Fierce Biotech14h

Jazz pays Saniona $42.5M to add preclinical prospect to epilepsy ensemble

Jazz Pharmaceuticals has struck a deal to bolster its epilepsy ambitions, paying Saniona $42.5 million upfront for a ...
Fierce Biotech10h

IQVIA and Veeva go from adversaries to friends, ending legal spat and forming long-term pact

The years-long legal kerfuffle between IQVIA and Veeva Systems has come to a close, with the former adversaries ...
Fierce Biotech12h

After a ‘complete standstill,’ private biotech market reaches new normal, investor says

The first half of 2025 was brutal for biotech, but investors are still keen on therapeutics in several indications and silver linings exist, particularly for private companies.  | The first half of ...